TherapeuticsMD (TXMD) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
TherapeuticsMD Announces Third Quarter 2015 Financial Results
November 4, 2015 4:05 PM ESTTopline phase 3 data anticipated in fourth quarter for TX-004HR to treat symptoms of VVA
Completed enrollment in phase 3 Replenish Trial for first potential FDA-approved bio-identical oral combination hormone therapy
Management to host conference call today at 4:30 p.m. EST
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, today announced its third quarter financial results for the period ended September 30, 2015.
Recent and Third Quarter Developments
Revenues, net for the... More